Cargando…

Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study

Objective To provide absolute and relative risk estimates of neonatal abstinence syndrome (NAS) based on duration and timing of prescription opioid use during pregnancy in the presence or absence of additional NAS risk factors of history of opioid misuse or dependence, misuse of other substances, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Rishi J, Huybrechts, Krista F, Hernandez-Diaz, Sonia, Mogun, Helen, Patorno, Elisabetta, Kaltenbach, Karol, Kerzner, Leslie S, Bateman, Brian T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431352/
https://www.ncbi.nlm.nih.gov/pubmed/25975601
http://dx.doi.org/10.1136/bmj.h2102
_version_ 1782371331641180160
author Desai, Rishi J
Huybrechts, Krista F
Hernandez-Diaz, Sonia
Mogun, Helen
Patorno, Elisabetta
Kaltenbach, Karol
Kerzner, Leslie S
Bateman, Brian T
author_facet Desai, Rishi J
Huybrechts, Krista F
Hernandez-Diaz, Sonia
Mogun, Helen
Patorno, Elisabetta
Kaltenbach, Karol
Kerzner, Leslie S
Bateman, Brian T
author_sort Desai, Rishi J
collection PubMed
description Objective To provide absolute and relative risk estimates of neonatal abstinence syndrome (NAS) based on duration and timing of prescription opioid use during pregnancy in the presence or absence of additional NAS risk factors of history of opioid misuse or dependence, misuse of other substances, non-opioid psychotropic drug use, and smoking. Design Observational cohort study. Setting Medicaid data from 46 US states. Participants Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (≥30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed. Main outcome measure Diagnosis of NAS in liveborn infants. Results 1705 cases of NAS were identified among 290 605 pregnant women filling opioid prescriptions, corresponding to an absolute risk of 5.9 per 1000 deliveries (95% confidence interval 5.6 to 6.2). Long term opioid use during pregnancy resulted in higher absolute risk of NAS per 1000 deliveries in the presence of additional risk factors of known opioid misuse (220.2 (200.8 to 241.0)), alcohol or other drug misuse (30.8 (26.1 to 36.0)), exposure to other psychotropic medications (13.1 (10.6 to 16.1)), and smoking (6.6 (4.3 to 9.6)) than in the absence of any of these risk factors (4.2 (3.3 to 5.4)). The corresponding risk estimates for short term use were 192.0 (175.8 to 209.3), 7.0 (6.0 to 8.2), 2.0 (1.5 to 2.6), 1.5 (1.0 to 2.0), and 0.7 (0.6 to 0.8) per 1000 deliveries, respectively. In propensity score matched analyses, long term prescription opioid use compared with short term use and late use compared with early use in pregnancy demonstrated greater risk of NAS (risk ratios 2.05 (95% confidence interval 1.81 to 2.33) and 1.24 (1.12 to 1.38), respectively). Conclusions Use of prescription opioids during pregnancy is associated with a low absolute risk of NAS in the absence of additional risk factors. Long term use compared with short term use and late use compared with early use of prescription opioids are associated with increased NAS risk independent of additional risk factors.
format Online
Article
Text
id pubmed-4431352
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-44313522015-05-15 Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study Desai, Rishi J Huybrechts, Krista F Hernandez-Diaz, Sonia Mogun, Helen Patorno, Elisabetta Kaltenbach, Karol Kerzner, Leslie S Bateman, Brian T BMJ Research Objective To provide absolute and relative risk estimates of neonatal abstinence syndrome (NAS) based on duration and timing of prescription opioid use during pregnancy in the presence or absence of additional NAS risk factors of history of opioid misuse or dependence, misuse of other substances, non-opioid psychotropic drug use, and smoking. Design Observational cohort study. Setting Medicaid data from 46 US states. Participants Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (≥30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed. Main outcome measure Diagnosis of NAS in liveborn infants. Results 1705 cases of NAS were identified among 290 605 pregnant women filling opioid prescriptions, corresponding to an absolute risk of 5.9 per 1000 deliveries (95% confidence interval 5.6 to 6.2). Long term opioid use during pregnancy resulted in higher absolute risk of NAS per 1000 deliveries in the presence of additional risk factors of known opioid misuse (220.2 (200.8 to 241.0)), alcohol or other drug misuse (30.8 (26.1 to 36.0)), exposure to other psychotropic medications (13.1 (10.6 to 16.1)), and smoking (6.6 (4.3 to 9.6)) than in the absence of any of these risk factors (4.2 (3.3 to 5.4)). The corresponding risk estimates for short term use were 192.0 (175.8 to 209.3), 7.0 (6.0 to 8.2), 2.0 (1.5 to 2.6), 1.5 (1.0 to 2.0), and 0.7 (0.6 to 0.8) per 1000 deliveries, respectively. In propensity score matched analyses, long term prescription opioid use compared with short term use and late use compared with early use in pregnancy demonstrated greater risk of NAS (risk ratios 2.05 (95% confidence interval 1.81 to 2.33) and 1.24 (1.12 to 1.38), respectively). Conclusions Use of prescription opioids during pregnancy is associated with a low absolute risk of NAS in the absence of additional risk factors. Long term use compared with short term use and late use compared with early use of prescription opioids are associated with increased NAS risk independent of additional risk factors. BMJ Publishing Group Ltd. 2015-05-14 /pmc/articles/PMC4431352/ /pubmed/25975601 http://dx.doi.org/10.1136/bmj.h2102 Text en © Desai et al 2015 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Desai, Rishi J
Huybrechts, Krista F
Hernandez-Diaz, Sonia
Mogun, Helen
Patorno, Elisabetta
Kaltenbach, Karol
Kerzner, Leslie S
Bateman, Brian T
Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title_full Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title_fullStr Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title_full_unstemmed Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title_short Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
title_sort exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431352/
https://www.ncbi.nlm.nih.gov/pubmed/25975601
http://dx.doi.org/10.1136/bmj.h2102
work_keys_str_mv AT desairishij exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT huybrechtskristaf exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT hernandezdiazsonia exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT mogunhelen exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT patornoelisabetta exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT kaltenbachkarol exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT kerznerleslies exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy
AT batemanbriant exposuretoprescriptionopioidanalgesicsinuteroandriskofneonatalabstinencesyndromepopulationbasedcohortstudy